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Progress in the molecular characterization of monogenic skin disorders
has been a hallmark of the past decade in investigative dermatology
and has, for the first time, brought the possibility of corrective genetic
therapies within reach. In addition to identification of disease genes,
successful corrective gene delivery to the skin requires an understanding
of disease pathogenesis, gene expression characteristics, stem cell
biology, effective gene delivery, and immune modulation (Vogel, 1993;
Greenhalgh et al, 1994; Krueger et al, 1994; Taichman, 1994; Khavari
and Krueger, 1997; Khavari, 1997). Because of its accessibility, the
skin offers an attractive opportunity to refine gene transfer capabilities
relative to current efforts underway in visceral tissues (Davis et al, 1996;
Hess, 1996; Sokol and Gewirtz, 1996; Blau and Khavari, 1997).
Progress in cutaneous gene therapy, however, has lagged behind other
tissues and future advances depend on rigorous studies in well-defined
skin disease model systems. In this review, I focus on the current
progress in therapeutic gene transfer for genetic skin disease and outline
future directions in the field.
SELECTED CANDIDATE GENETIC SKIN DISEASES
The genetic basis for a number of hereditary skin diseases has been
elucidated (Table I), with remaining uncharacterized genodermatoses
currently the focus of intensive investigation. Human genetic lesions
leading to skin blistering, abnormal cutaneous cornification, and
cancer predisposition have been well characterized. In the epidermis,
these mutations affect genes expressed selectively in either basal or
suprabasal layers, as well as those expressed in both compartments.
The site of such genetic defects within the epidermis can produce
characteristic corresponding phenotypic abnormalities. Mutations in
important basal layer genes commonly lead to skin fragility and
blistering, such as is seen with laminin 5 chain gene defects in a
subset of junctional epidermolysis bullosa patients (Aberdam et al,
1994; Eady and Dunnill, 1994; Pulkkinen et al, 1994; Uitto and
Pulkkinen, 1996). Suprabasal defects lead to abnormal terminal
epidermal differentiation often manifested as hyperkeratosis, as seen
in the case of transglutaminase 1 gene mutations in lamellar ichthyosis
(Russell et al, 1994, 1995; Huber et al, 1995a). A number of these
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disorders, especially those involving mutations in large structural
proteins such as type VII collagen in dystrophic epidermolysis
bullosa (Christiano et al, 1993, 1994; Hilal et al, 1993), are likely
to be intractable to small molecule pharmacotherapy and may be
only effectively approached by the return of normal protein
expression.
An understanding of the molecular basis of disease pathogenesis
in these disorders is important in the design of rational genetic
therapies. Correction of recessive disorders, in principal, requires
only re-expression of the normal protein product corresponding to
the previously absent or defective genes. This has been recently
achieved in model efforts, as noted below (Choate et al, 1996a, b;
Freiberg et al, 1997). A greater challenge exists in the dominant
disorders due to dominant-negative mutant proteins that effectively
‘‘poison’’ any wild type protein present, as in the case of keratin 1
and 10 mutants in epidermolytic hyperkeratosis (Cheng et al, 1992;
Rothnagel et al, 1992). Effective genetic correction in these latter
instances requires circumventing the negative effects of such mutants
in an effort to restore the function of the normal protein. Because
of the considerable additional technical challenges associated with
gene delivery to human somatic tissue, the recessive genetic skin
disorders have been the focus of many current efforts to date.
SPECIFIC REQUIREMENTS OF GENODERMATOSES
COMPARED WITH OTHER CUTANEOUS GENE
TRANSFER APPLICATIONS
A recurrent theme in gene therapy efforts in all tissues is the need to
tailor gene transfer approaches to specific therapeutic applications (Blau
and Khavari, 1997). In addition to genetic skin diseases, the skin is a
potential tissue site for a number of distinct therapeutic gene transfer
efforts and these differ considerably in their gene transfer requirements.
Such potential efforts include cutaneous gene transfer for immunization
(Raz et al, 1994) and for production of polypeptides for delivery to
the systemic circulation (Fenjves et al, 1989; Fenjves et al, 1994). Each
of these three applications has distinctive requirements regarding
efficiency of gene transfer, durability, regulation of
expression of the introduced gene (the ‘‘transgene’’), and transgene
immunogenicity.
High efficiency gene transfer that restores normal gene expression
to all cells of a diseased tissue has been among the most challenging
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Table I. Selected candidate genodermatoses
Disordera Selected gene(s) References
Lamellar ichthyosis subset Transglutaminase 1 Huber et al, 1995a; Russell et al, 1995
X-linked ichthyosis Steroid sulfatase Yen et al, 1987
EB simplex Keratins 5 and 14 Bonifas et al, 1991; Coulombe et al, 1991
Pachyonychia congenita type 1/2 Keratins 6a and 16/17 Bowden et al, 1995; McLean et al, 1995
Epidermolytic hyperkeratosis Keratins 1 and 10 Cheng et al, 1992; Rothnagel et al, 1992
Epidermolytic PPK Keratin 9 Reis et al, 1994; Torchard et al, 1994
Non-epidermolytic PPK Keratin 16 Shamsher et al, 1995
Vohwinkel’s syndrome Loricrin Maestrini et al, 1996
Ichthyosis bullosa of Siemens keratin 2e Rothnagel et al, 1994
Junctional EB Laminin 5 α3, β3 and γ2 Aberdam et al, 1994; Pulkkinen et al, 1994
BPAG2 [BP180] McGrath et al, 1995
β4 integrin Vidal et al, 1995
Plectin Smith et al, 1996
Dystrophic EB Type VII collagen Christiano et al, 1993; Hilal et al, 1993
Xeroderma pigmentosum XP group genes Li et al, 1993; Kraemer, 1996
Basal cell nevus syndrome Patched Hahn et al, 1996; Johnson et al, 1996
aEB, epidermolysis bullosa; PPK, palmoplantar keratoderma; XP, xeroderma pigmentosum.
goals in many tissues; however, not all applications require it. Immuniza-
tion via gene transfer to the skin, for example, depends on immune
elements in skin and does not require uniform transgene delivery to
all cells in a given tissue compartment. This may also be the case in
systemic delivery of proteins expressed in skin, where the absolute
magnitude of total transgene product delivered from the skin impacts
the therapeutic outcome more that the percentage of cells in the skin
that express it. Lasting correction of genetic skin disease, in contrast,
may require high efficiency gene transfer, as could be predicted in the
case of cancer prevention in patients with xeroderma pigmentosum
and in the correction of cell-intrinsic structural defects such as keratin
5/14 mutations in epidermolysis bullosa simplex (Bonifas et al, 1991;
Coulombe et al, 1991). In such cases, a focal lack of corrective gene
expression may be sufficient to perpetuate major elements of disease
pathology (i.e., neoplastic transformation in xeroderma pigmentosum
and skin fragility in epidermolysis bullosa). High efficiency genetic
correction therefore may be of importance in gene therapy of genoder-
matoses.
Gene transfer efforts in human visceral tissues have been unsuccessful
in reliably sustaining therapeutic gene expression (Davis et al, 1996;
Hess, 1996; Sokol and Gewirtz, 1996; Blau and Khavari, 1997), and
the ability to sustain therapeutic gene delivery for prolonged periods
is another capability important in gene therapy for genetic skin disease.
Whereas the need for such long-term gene delivery may be variable
to nonexistent in both genetic immunization and protein delivery to
the circulation from the skin, curative efforts in genodermatoses depend
on lasting restoration of normal gene expression. Because this requires
durable gene delivery vectors, gene targeting to long-lived skin stem
cells, and avoidance of immune clearing, achieving such sustainability
has proven to be a formidable challenge. Whereas periodic read-
minstration of therapeutic genes in the form of grafting with genetically
engineered cells or by direct transfer of vectors to intact human skin
tissue may be envisioned in certain lethal genetic skin disorders,
achievement of sustainable cutaneous gene delivery is a major require-
ment for ultimate success.
The skin, by virtue of its accessibility to target gene regulation by
topically applied agents, is an attractive tissue for regulated therapeutic
gene production. Such regulated delivery may be of importance in the
delivery of proteins to the systemic circulation, such as the hemato-
poietic growth factor erythropoeitin (Bohl et al, 1997). Many of the
genes affected in genetic skin disease, however, are expressed at constant
levels within a given tissue compartment, as in the case of laminin 5
and keratin genes within the basal and suprabasal layers, respectively.
Precise regulation of the magnitude of therapeutic gene expression in
genetic skin disease may therefore be unneeded in most cases, provided
gene expression may be restored to levels within a physiologic range.
The ability of a therapeutic transgene to induce a specific immune
response, although central for the success of intradermal genetic
immunization, represents a feared complication in gene transfer efforts
for monogenic skin disease. Surprisingly, such unwanted transgene
specific immune responses have not been widely reported in current
gene therapy trials in other tissues, in stark contrast to inflammatory
responses seen in humans with viral gene delivery vectors such as
adenovirus (Knowles et al, 1995). Because current pre-clinical models
of therapeutic cutaneous gene transfer lack an intact human immune
system, the extent to which unwanted immune reactions will pose a
challenge may only become clear in human clinical trials. Central
requirements for successful genetic correction of genetic skin disease,
then, may include high efficiency genetic correction, durabilty, consist-
ent transgene expression levels, and a lack of unwanted immune
clearing of the therapeutic gene.
PROGRESS IN SPECIFIC GENODERMATOSES
Recessive ichthyoses The ichthyotic disorders are a heterogeneous
family of diseases characterized by abnormal epidermal cornification
(Williams and Elias, 1987). Recently the genetic basis for several of
these disorders has been characterized (Bale and Doyle, 1994) and
found to involve key enzymatic or structural proteins involved in
epithelial maturation and cutaneous barrier function. Among the
recessive ichthysoses are lamellar ichthyosis and X-linked recessive
ichthyosis. Consistent with the nature of their gene defects in the
suprabasal epidermal gene expression program, these disorders are
characterized by clinical hyperkeratosis.
Lamellar ichthyosis has been associated with the TGM1 gene (Russell
et al, 1994, 1995; Huber et al, 1995a) in a subset of patients by genetic
linkage and mutation analysis, and has proven to be a valuable prototype
disorder for gene therapy (Choate et al, 1996a, b) due to its dramatic
clinical and biochemical phenotype. The TGM1 gene encodes ker-
atinocytes transglutaminase (TGase1) (Thacher et al, 1985; Phillips et al,
1990), a membrane linked enzyme active in forming the cornified
envelope in differentiating keratinocytes. TGase1 catalyzes the forma-
tion of isodipeptide cross-links between cornified envelope precursor
molecules (Greenberg et al, 1991; Kim et al, 1995) and is believed
necessary for normal terminal differentiation and barrier formation in
the outer epidermis. Although not present in all lamellar ichthyosis
patients (Bale et al, 1994; Huber et al, 1995b; Parmentier et al, 1995),
TGM1 gene mutations in affected patients may produce enzymatically
inactive TGase1 protein (Huber et al, 1995a). Restoration of functional
TGase1 enzymatic activity to skin from TGase1-negative patients
represents a possible means of correcting this disorder.
In order to achieve this, recent work has developed an approach to
achieving high efficiency transfer of the normal TGase1 gene to skin
from patients characterized as TGase1-negative (Choate et al, 1996a).
This approach relies on amphotropic retroviral gene delivery vectors
for the TGase1 gene (Choate et al, 1996a). Following high efficiency
gene transfer into primary patient keratinocytes grown in vitro, restora-
tion of full length TGase1 protein expression and transglutaminase
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enyzmatic activity was verified. These keratinocytes were then grafted
to immune deficient mice to regenerate human skin in vivo in an
approach that recapitulates the histologic, gene expression, clinical, and
functional features of human skin in vivo (Choate et al, 1996b; Medalie
et al, 1996; Choate and Khavari, 1997a), with the exception of
immune function. Lameller ichthyosis patient keratinocytes genetically
engineered with the TGase1 vector regenerated skin displaying restored
TGase1 protein expression in vivo and was normalized at the levels of
histology, clinical surface appearance, and barrier function; patient cells
that received a control vector produced skin with the hyperkeratosis
and defective skin barrier function characteristic of the disease (Choate
et al, 1996b). These findings indicated that successful phenotypic
correction of human genetic skin disease tissue can be achieved via
this gene transfer approach; however, this correction failed to extend
beyond the 1 month timepoint after which transgene expression is
commonly lost in many cutaneous gene transfer models (Gerrard et al,
1993; Taichman, 1994; Choate et al, 1996b; Fenjves et al, 1996; Choate
and Khavari, 1997a; Freiberg et al, 1997). Such loss may be due to a
number of potential factors; however, in this approach it appears to be
due to silencing of vector promoter elements (Choate and Khavari,
1997a). Correction of lamellar ichthyosis patient skin tissue, then,
could be achieved but not sustained.
X-linked ichthyosis is a genodermatosis that is generally much milder
than lamellar ichthyosis (Williams and Elias, 1987; Paige et al, 1994).
Due to a loss of functional Arylsulfatase C (Yen et al, 1987; Shapiro
et al, 1989; Alperin and Shapiro, 1994; Ballabio and Shapiro, 1995), a
steroid sulfatase believed necessary for a normal desquamation (Epstein
et al, 1981), X-linked ichthyosis constitutes another prototype recessive
disorder for refinement of cutaneous gene transfer. High efficiency
retroviral gene transfer followed by grafting of genetically engineered
cells has also recently been used to correct X-linked ichthyosis patient
skin at the level of tissue architecture, gene expression, clinical
appearance, and function (Freiberg et al, 1997). Although also not
sustained for periods significantly longer than 1 month, this corrective
gene transfer disease model offers another opportunity to address the
challenge of durable therapeutic gene delivery to the skin.
Among the other inherited disorders of cornification are dominant
disorders due to keratin mutations, such as epidermolytic hyperkeratosis
(K1/K10) (Cheng et al, 1992; Rothnagel et al, 1992), palmoplantar
keratoderma subtypes (epidermolytic, K9; nonepidermolytic, K16)
(Reis et al, 1994; Torchard et al, 1994; Shamsher et al, 1995), and
pachyonychia congenita subtypes (K6a/16/17) (Bowden et al, 1995;
McLean et al, 1995). In principal, these diseases represent much greater
challenges to even achieving short-term correction than the recessive
disorders because of the presence of proposed dominant-negative
mutant keratin molecules. Additional wild type gene expression in this
setting may be ineffective because such mutants can disrupt the function
of normal keratin subunits in forming the intermediate filaments that
give structural integrity to the cell (Freedberg, 1993; Fuchs, 1995). A
number of strategies to overcoming the challenge of dominant-negative
mutants via genetic approaches are being studied, including in situ
gene repair by oligonucleotide recombination and homologous gene
recombination; however, none have yet been shown successful in
achieving functional correction in a genodermatosis model.
Epidermolysis bullosa The array of inherited blistering skin dis-
orders known as epidermolysis bullosa represent prototypes of gene
defects in affecting the basal epidermal program of gene expression
(Eady and Dunnill, 1994; Uitto et al, 1994; Korge and Krieg, 1996;
Paller, 1996; Uitto and Pulkkinen, 1996). The recent characterization
of the genes responsible for specific subtypes of this disease have
revealed a corresponding heterogeneity in molecular defects (Table I).
A common theme emerging from these studies has been that these
defects affect structural proteins, forming the vital link from the
cytoplasm of basal keratinocytes through basement membrane zone
components and on down into the uppermost dermis (Uitto and
Pulkkinen, 1996). Because of the structural nature of these proteins
and the fact that many have multiple functional domains and can
polymerize to form higher order structures, purely medicinal therapy
has proven of little benefit. Especially in the case of more severe
subtypes of epidermolysis bullosa, a key hope centers on correction of
specific underlying genetic defects.
Molecular alterations in a number of specific genes responsible for
epidermolysis bullosa have been increasingly well characterized over
the past 5 y (Marinkovich, 1993; Uitto et al, 1994; Korge and Krieg,
1996; Paller, 1996; Uitto and Pulkkinen, 1996). Malfunction in any
of their corresponding proteins mediating epidermal adhesion, which
could be envisioned to function as a series of connected links in a
chain, results in skin fragility and blistering. The association of these
genes with specific clinical phenotypes has shed additional light on their
pathogenesis, as, for example, in the case of compound heterozygous
mutations identified in the type VII collagen gene in dystrophic
epidermolysis bullosa (Tamai et al, 1997), as well as BPAG2 (McGrath
et al, 1996b) and laminin 5 chains (Christiano et al, 1996; McGrath
et al, 1996a) in junctional epidermolysis bullosa. The majority of genes
implicated in epidermolysis bullosa are effectively produced within
keratinocytes of the basal epidermal layer (Marinkovich et al, 1993).
This, combined with the fact that some of these genes are expressed
in internal epithelia in addition to skin, underscores the fact that
attempts at genetic correction in these disorders must be correctly
targeted. In this regard, it is unknown whether restored expression of
a basement membrane protein throughout the epidermis may result in
disordered epithelial polarity, therefore it is formally possible that
proteins such as laminin 5 and BPAG2 require expression limited to
the basal epidermal layer. This is in contrast to corrective efforts with
TGase1 and steroid sulfatase where mRNA expression throughout the
epidermis via vector promoters active in all layers failed to impair their
corrective impact (Choate et al, 1996b; Freiberg et al, 1997). The fact
that genetically corrected epidermolysis bullosa patient keratinocytes
may have a selective adhesive advantage over uncorrected cells,
however, may mitigate against these and other unanticipated poten-
tial pitfalls.
Although at an earlier stage than the ichthyoses, efforts at genetic
correction of epidermolysis bullosa in model systems have focused on
laminin 5 (Gagnoux-Palacios et al, 1996) and BPAG2 in junctional
disease and type VII collagen in the dystrophic subtypes. It is interesting
to note that revertant mosaicism in the BPAG2 gene – where a
defective gene reverts to normal in a mosaic pattern in the skin – has
been described in generalized benign atrophic epidermolysis bullosa,
and has been noted to resemble a natural form of cutaneous gene
therapy (Jonkman et al, 1997). In the case of laminin 5, defects in one
of the three chains of the laminin 5 trimer (α3, β3, or γ2) are associated
with junctional epidermolysis bullosa of a severity that extends to
include the severe Herlitz subtype (Aberdam et al, 1994; Pulkkinen
et al, 1994; Uitto et al, 1994). Laminin 5 γ2 chain gene transfer via
both modified adenoviral and retroviral based approaches has been
described in the immortalized L5 V5 keratinocyte line (Gagnoux-
Palacios et al, 1996). Such gene transfer led to restoration of normal
features of laminin 5 trimer expression in a basal polarized fashion and
this finding was confirmed in cysts of immortalized cells formed in vivo
after subcutaneous injection into nude mice (Gagnoux-Palacios et al,
1996). A next phase of work in genetic correction of epidermolysis
bullosa will involve nontransformed tissue from patients in spatially
intact epidermis.
Xeroderma pigmentosum Xeroderma pigmentosum has been
associated with defects in a number of DNA repair genes and is
characterized by specific inadequacies in DNA repair following ultravi-
olet injury (Li et al, 1993; Kraemer, 1996). From the standpoint of
gene targeting, xeroderma pigmentosum represents a pan-epidermal
prototype disorder affecting both basal and suprabasal compartments,
including melanocytes. The disease is characterized by photosensitivity
with early onset of cutaneous neoplasias, including basal cell carcinoma,
squamous cell carcinoma, and melanoma (Kraemer et al, 1990). Much
progress has been made in identifying the genes corresponding to the
separate genetic complementation groups of xeroderma pigmentosum
and its variants. This progress has been followed by attempts at genetic
correction in xeroderma pigmentosum cells grown in tissue culture.
The XPA and XPD genes have been among those best studied in this
regard and their restoration to cells lacking these genes has been shown
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Figure 1. Paradigm for development of gene therapy for genetic skin disease.
to return parameters of DNA repair and cell survival after ultraviolet
injury back toward normal (Marionnet et al, 1993; Myrand et al,
1996). While corrective gene delivery to all layers of the epithelium
is readily achieved to keratinocytes by regeneration of skin using
genetically engineered cells (Choate et al, 1996b; Freiberg et al, 1997),
the need to target melanocytes represents an additional formidable
challenge in xerodermal pigmentosum that has not yet been systematic-
ally approached. Xeroderma pigmentosum, then, represents another
serious genetic disorder in which efforts in models of genetic correction
have been initiated yet in which major technical challenges remain.
REQUIRED NEW CAPABILITIES AND ALTERNATIVE
APPROACHES
Widespread successful application of genetic therapies in the treatment
of genetic skin disease is dependent upon the advancement of our
understanding of fundamental biologic processes in the skin as well as
the acquisition of new gene delivery capabilities (Fig 1). Important
biologic questions in therapeutic gene transfer involve the characteriza-
tion of cutaneous stem cells and an increased understanding of cutaneous
gene expression. Although impressive advances have recently been
made in our understanding of the characteristics of epidermal stem
cells (Jones and Watt, 1993; Rochat et al, 1994; Bata-Csorgo et al,
1995; Jones et al, 1995; Mathor et al, 1996), no markers solely specific
for these cells have yet been identified. Furthermore, our understanding
of the factors controlling stem cell division and the genetic programs
unique to these tissue progenitors is still in the early stages. In addition
to targeting genetic elements to stem cells, long-term corrective gene
delivery requires sustained transgene expression. Such expression is
dependent on the gene regulatory milieu within a given tissue and, as
noted above, this has not supported the achievement of long-term
uniform gene expression throughout genetically engineered skin tissue
by current approaches, even when vector sequences persist (Gerrard
et al, 1993; Taichman, 1994; Choate et al, 1996b; Fenjves et al, 1996;
Choate and Khavari, 1997a; Freiberg et al, 1997). The factors causing
this loss of transgene expression may involve mechanisms fundamental
to eukaryotic gene regulation, such as promoter methylation and
heterochromatin formation (Hoeben et al, 1991; Wolffe, 1992).
Recently, however, new vectors have been developed that show
promise in achieving longer term gene expression in human epidermis
(Deng et al, 1997). An understanding of fundamental relevant biologic
processes will then be important to future improvements in cutaneous
gene transfer.
Parallel to these advances in fundamental skin biology, new technical
capabilities in gene delivery are required for sustained genetic correction
of the genodermatoses. Among these are development of highly
efficient vectors that can be directly administered to intact skin without
unwanted immune hypersensitivity reactions. Current viral and nonviral
approaches for direct gene transfer fail to meet this criteria (Hengge
et al, 1995; Lu et al, 1997). An unsuccessful attempt to correct human
lamellar ichthyosis patient skin tissue by direct TGase1 expression
plasmid injection highlights some of the current challenges facing this
approach to gene therapy for genodermatoses (Choate and Khavari,
1997b). The development of new vectors and the use of immune
down-modulation by blockade of costimulatory molecules such as
CD28 and CD40 (Larsen et al, 1996) shows some promise in this
regard. A lack of intrinsic vector stamina, however, must be addressed
as well and the characterization of genetic elements conferring durable
expression on therapeutic vector sequences is an important effort in
achieving lasting genetic correction.
Correction of abnormal gene expression in genodermatoses may be
approached by avenues distinct from transfer of the normal gene.
Among such methods are oligonucleotide based repair of mutated
genes by genetic recombination, direct application of recombinant
proteins to affected skin, and heterologous cell therapy that circumvents
immune rejection. These approaches, along with other emerging
innovative strategies, may offer attractive future ways to avoid the
traumatic and complicated process of grafting genetically engineered
cells, which represents a current focus of models of gene therapy of
genetic disease.
SUMMARY AND CONCLUSIONS
With identification of the genes involved in the pathogenesis of a
number of inherited cutaneous disorders, the previously bleak prospects
for patients afflicted by an array of genodermatoses may be changing
for the better; however, realistic assessment of the formidable challenges
remaining to routinely achieving corrective gene delivery in the skin,
indicate that significant additional progress is required before this
technology becomes widely applicable to these patients. Nevertheless,
advances in new models of in vivo genetic correction highlight the
potential promise for future successful application to patients afflicted
with genetic skin disease.
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